Dupixent and T-Cell Lymphoma – What Eczema and Asthma Patients Need to Know

A federal judicial panel formed a Dupixent lawsuit MDL on June 5, 2026. That’s not a headline most eczema or asthma patients expected to read about a drug their dermatologist or allergist handed them like a solution. If you or someone you love used Dupixent for months or years and later received a T-cell lymphoma diagnosis, you’re probably asking the same question every client calls me with in these cases. Did the drug that was supposed to clear my skin actually hide something far more serious underneath it?

My name is Robert Baker. I’ve spent more than thirty years trying cases against corporations and drug manufacturers, and I served as Rhode Island’s State Liaison Counsel during the multidistrict breast implant litigation in the early 1990s, coordinating claims against a manufacturer that also downplayed a serious risk for years. That background matters here, because a Dupixent lymphoma lawsuit isn’t a form you fill out and forget about. It’s a case that requires someone who has actually coordinated mass tort litigation before, not a call center that signs you up and passes your file along to whoever bids the lowest.

Here’s what I want to walk you through. What cutaneous T-cell lymphoma actually is and why Dupixent is connected to it. How we got from scattered case reports to a formal multidistrict litigation in New Jersey. Whether your specific situation fits the eligibility picture we’re seeing so far. And why “my doctor never brought this up” is such a common response, and not a coincidence.

What Cutaneous T-Cell Lymphoma Actually Is – and Why Dupixent Is Connected to It

Cutaneous T-cell lymphoma, or CTCL, is a rare cancer that starts in white blood cells called T-cells and shows up on the skin. The two forms you’ll hear about most often are mycosis fungoides and its more advanced cousin, Sézary syndrome. Here’s the part that should concern anyone who’s been prescribed Dupixent for stubborn eczema. In its early stages, CTCL can look almost identical to atopic dermatitis. Red, scaly, itchy patches. The kind of presentation that sends a patient straight to a dermatologist asking for relief, not a biopsy.

Dupixent works by blocking a pair of proteins, interleukin-4 and interleukin-13, that drive the inflammation behind eczema, asthma, and several other type 2 immune conditions. For most patients with genuine atopic dermatitis, blocking that pathway calms the skin down. But dermatology researchers have documented a troubling pattern in patients who actually had undiagnosed CTCL masquerading as eczema. When Dupixent suppresses the visible inflammatory response, it can mask the underlying lymphoma rather than treat it, allowing the disease to progress quietly while the skin looks like it’s improving. We break down the masking effect behind these misdiagnoses in more detail.

There’s a second, separate concern showing up in the medical literature and FDA adverse event reports. In some patients, physicians and researchers have raised the question of whether Dupixent doesn’t just mask an existing CTCL, but may actually accelerate or unmask a T-cell process that hadn’t fully declared itself yet. Case reports have described patients developing biopsy-confirmed mycosis fungoides or progressing to Sézary syndrome during Dupixent treatment, sometimes after the drug had been credited with initially calming their skin.

I want to be exact about what this means for you. Not everyone who takes Dupixent and later develops CTCL has a case against the manufacturer. What matters is whether the company understood this masking and unmasking risk, when it understood it, and whether that risk reached the people prescribing the drug and the patients taking it. That’s the same question I asked about Yamaha’s jet ski defect and about the breast implant manufacturer I helped hold accountable three decades ago. What did the company know, and what did it do with that knowledge.

Signs Worth Raising With Your Doctor

I’m not a physician, and nothing here replaces an actual medical evaluation. But patients and families researching this litigation consistently describe a few patterns worth mentioning at your next appointment, especially if you’ve been on Dupixent for an extended period.

• A patch that stops responding. Eczema that improved on Dupixent and then plateaued, or one specific patch that never cleared while everything else did.
• New lesions with a different texture or color. Patches that feel thicker, more raised, or scalier than your typical eczema pattern, sometimes described as looking more like a rash that won’t behave the way the rest of your skin does.
• Swollen lymph nodes without another explanation. Especially when paired with skin changes that haven’t resolved.
• A diagnosis that shifted over time. Some patients describe being told their eczema was simply “resistant” or “atypical” for months before a biopsy finally identified CTCL.

None of these symptoms confirm a lymphoma diagnosis on their own, and I’d never suggest otherwise. What they do is give you specific language to bring to your dermatologist instead of a vague sense that something feels off. If a biopsy or referral to an oncologist follows from that conversation, that’s the outcome that matters, regardless of what it ultimately shows.

How the Litigation Timeline Led to MDL No. 3180

Mass tort litigation doesn’t happen overnight, and it doesn’t happen because a handful of patients feel like something went wrong. It happens because a documented pattern builds across independent cases until a federal panel decides the evidence warrants coordinated handling.

• FDA adverse event reports accumulated. Physicians and patients submitted reports connecting Dupixent use to new or progressing CTCL diagnoses through the FDA’s adverse event reporting system, the same reporting channel that eventually surfaces most drug safety signals before litigation catches up to them.
• Wrongful death cases followed the pattern. As Sézary syndrome and advanced mycosis fungoides cases connected to Dupixent use began reaching courts individually, families who lost loved ones to a disease that had been treated as manageable eczema for months or years started filing claims of their own.
• Individual filings converged on a common legal theory. Enough separate cases raised the same core allegation – failure to adequately warn about the masking and unmasking risk – that the cases became candidates for coordination rather than scattered litigation across dozens of courts.
• The Judicial Panel on Multidistrict Litigation stepped in. On June 5, 2026, the panel formed MDL No. 3180 in the District of New Jersey, assigning the consolidated litigation to Judge Quraishi. Consolidation doesn’t combine your case with anyone else’s for purposes of your compensation. It combines the shared questions, like what the manufacturer knew about the CTCL connection, so they get answered once instead of relitigated case by case.

If you want to read directly from the source rather than take a law firm’s word for how these panels work, the U.S. Judicial Panel on Multidistrict Litigation publishes its transfer orders and case assignments publicly. I’d rather you verify the mechanics yourself than assume I’m the only place to find that information.

An MDL forming is a strong signal that a legal claim has real substance. It’s not a settlement, and it’s not a promise about your individual case’s value. What it does mean is that a federal court has looked at the volume and pattern of these claims and decided they deserve coordinated discovery into what the manufacturer knew and when.

Do You Qualify for a Dupixent Lymphoma Claim

Every mass tort intake starts with the same honest answer from me. It depends on your specific medical history, and I won’t know for certain until we review your records. But the eligibility framework we’re seeing take shape looks like this.

• You used Dupixent for at least one month. The masking and unmasking concern is tied to sustained use, not a single dose or a brief trial period.
• You received a CTCL diagnosis after starting Dupixent. This includes mycosis fungoides, Sézary syndrome, or another form of cutaneous T-cell lymphoma diagnosed during or after your treatment course.
• You had no pre-existing lymphoma diagnosis before starting Dupixent. This is one of the more important distinctions in these cases. If your CTCL was already diagnosed before you started the drug, that’s a different situation than a diagnosis that emerged, or was uncovered, during treatment.
• You were originally treated for atopic dermatitis, asthma, or another approved Dupixent indication. The eligibility picture centers on patients who were prescribed the drug in good faith for a condition it’s approved to treat, not an off-label use.

If you’re reading this list and thinking “that sounds like exactly what happened to me,” that reaction is worth taking seriously enough to make a phone call. If you’re reading it and something doesn’t quite fit, that’s worth a phone call too. Eligibility frameworks describe patterns, not hard rules, and the details of your medical chart matter more than any bullet point on a website.

“My Doctor Never Mentioned This” – Why That’s Not Surprising

I hear this same sentence in nearly every mass tort case I’ve worked, going back to the breast implant litigation I coordinated in Rhode Island. Patients feel almost embarrassed admitting their doctor never raised the risk, as if they should have caught something their own physician didn’t flag. I want to address that directly, because it’s not a personal failing on your part or your doctor’s.

As of today, cutaneous T-cell lymphoma is not listed as a warning on Dupixent’s FDA label the way more established risks are. A physician relying on the official prescribing information has no label-driven reason to raise CTCL risk with a patient before starting treatment, and no built-in reason to biopsy a stubborn eczema patch before prescribing a drug that’s approved to treat exactly that kind of patch. That’s the entire problem at the center of this litigation. If the connection between Dupixent and CTCL masking was understood internally before it made it onto a label most physicians actually read, that’s the failure to warn question the MDL exists to answer.

Your dermatologist or allergist almost certainly practiced within the standard of care available to them. That doesn’t mean the information available to the manufacturer was the same information available to your doctor. Those are two different questions, and only one of them determines whether you have a claim against the drug manufacturer rather than a malpractice question against your physician.

What a Dupixent Product Liability Claim Actually Involves

A pharmaceutical mass tort case moves differently than a single-plaintiff injury claim, and it’s worth understanding that difference before you sign with anyone. You’re not proving a doctor made a mistake in your individual treatment. You’re proving that a manufacturer knew, or should have known, about a serious risk and failed to adequately warn the physicians prescribing its drug and the patients taking it.

That means discovery into internal company communications, clinical trial data, and the timeline between when adverse event reports started arriving and when, if at all, the company acted on them. It’s the same kind of case-building I did against Yamaha in the personal watercraft litigation that produced the largest verdict of its kind in U.S. history, and it’s the same coordination work I did decades earlier as State Liaison Counsel on the breast implant MDL. The specific product changes. The underlying question, what did the company know and what did it do about it, does not.

I bring that up because a lot of the firms advertising for Dupixent cases right now are aggregators. They collect sign-ups, bundle them, and hand the cases off to whichever litigation group actually tries them. I don’t operate that way. If I take your case, I’m an active trial attorney working it, not a referral desk. That distinction matters more in mass tort litigation than almost anywhere else, because these cases can take years, and you want the person who signed you up still involved when it matters most.

There’s also a broader pattern worth understanding if a defective medical product is part of your situation. Dupixent is a pharmaceutical, not an implanted device, but the underlying legal theory – a manufacturer that knew about a risk and didn’t adequately disclose it – runs through nearly every product liability case I’ve handled. If a defective medical device is part of your family’s story rather than a prescription drug, the details behind our Cartiva implant litigation walk through that same framework applied to a different product.

Mass Tort or Class Action – Why the Difference Matters to You

Patients researching this litigation almost always use the two terms interchangeably, and the difference actually changes what you can expect from your own case. A class action treats everyone in the class as a single unit. One outcome, divided among the group, with individual circumstances mostly flattened out. A mass tort, which is what MDL No. 3180 is, keeps every plaintiff’s case individual. Your medical history, your diagnosis timeline, and your damages stay yours. The MDL only coordinates the questions every case shares, like what the manufacturer knew about the CTCL risk and when.

We cover how that process actually works for someone filing an individual claim in more detail, including how bellwether trials fit in and what joining the MDL involves step by step.

That distinction matters because it means your compensation isn’t capped by a group settlement pool divided evenly across thousands of claimants regardless of how serious your diagnosis was. A patient who developed early-stage mycosis fungoides and a family who lost someone to Sézary syndrome do not have equivalent cases, and a properly run mass tort keeps that difference intact through resolution. Ask any attorney signing you up whether they’re preparing your case individually or simply adding your name to a list. The answer tells you a great deal about who you’re actually hiring.

Questions Dupixent Patients Ask Me Most

Should I stop taking Dupixent if I’m worried about this risk?
That’s a medical decision between you and your prescribing physician, not a legal one, and I won’t tell you otherwise. What I can tell you is that if you have new or worsening skin lesions that don’t match your prior eczema pattern, or if a patch has stopped responding to treatment the way it used to, that’s worth raising directly with your doctor and asking whether a biopsy makes sense.

What if my CTCL diagnosis came years after I stopped Dupixent?
It still may qualify. The masking effect this litigation centers on doesn’t necessarily resolve the moment you stop the drug, and a delayed diagnosis is part of the pattern we’re seeing, not an exception to it. Bring your full treatment timeline to the consultation and let us map it against your diagnosis date.

Do I need to have proof the company knew about the risk?
No. That’s exactly the kind of evidence discovery in the MDL is built to bring to light, and it’s not something an individual patient could access on their own. Your job is documenting your own medical history. Building the case against the manufacturer is mine.

How long will this take?
Mass tort litigation of this size typically moves through bellwether trials, a small number of representative cases tried first to establish how juries respond to the core evidence, before broader resolution takes shape across the remaining cases. That process runs on a timeline measured in years, not months, and I’d rather tell you that honestly now than let you assume otherwise.

What to Do If You Think You Have a Dupixent Lymphoma Case

Start by gathering what you can, even before you call anyone.

1. Pull your prescription history. The dates you started and stopped Dupixent matter more than you’d expect.
2. Get your diagnosis paperwork. Pathology reports and the date of your CTCL diagnosis are central to the timeline.
3. Note whether lymphoma was mentioned to you before treatment started. If it wasn’t, that’s relevant. If it was, that’s relevant too, just in a different way.
4. Don’t wait on a deadline you haven’t confirmed. Statutes of limitations vary by state and by claim type, and mass tort filing windows shift as litigation develops. Don’t assume you have unlimited time simply because the MDL was just formed.

From there, a free consultation is the fastest way to find out where you actually stand. I review the medical timeline, tell you honestly whether your situation fits the pattern we’re litigating, and if it does, you pay nothing unless we win. Not “no fees” with hidden costs tucked into the fine print. No fees and no costs, unless the case succeeds.

I’m selective about which cases I take on, the same way I’ve been selective throughout thirty years of trial work, because building a mass tort case correctly takes real time and real resources. But once I commit to your case, you have my personal involvement from intake through resolution, not a handoff to whichever associate has room on their desk.

If Dupixent masked or accelerated a T-cell lymphoma diagnosis in your life or a loved one’s, call me directly at 888-468-4608. You can also review my background and trial record on my Dupixent lawsuit case page. The consultation costs nothing, and it costs you nothing to find out whether the timeline in your case matches what this litigation is built around.